AKT1 and neoplasm: Although correlating with shortened patient survival, a potential dependence of Mic60-low tumors to GCN2/ISR/Akt adaptive signaling was therapeutically exploitable, and proof-of-concept studies shown here demonstrated that pharmacologic or genetic targeting of this pathway can restore mitochondrial cell death and inhibit proliferation selectively of Mic60-low tumor cells.